These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 33174513)
1. Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Kremer IEH; Hiligsmann M; Carlson J; Zimmermann M; Jongen PJ; Evers SMAA; Petersohn S; Pouwels XGLV; Bansback N Med Decis Making; 2020 Nov; 40(8):1003-1019. PubMed ID: 33174513 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891 [TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. Zhang X; Hay JW; Niu X CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785 [TBL] [Abstract][Full Text] [Related]
4. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001 [TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967 [TBL] [Abstract][Full Text] [Related]
6. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis. Soini E; Joutseno J; Sumelahti ML Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065 [TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Su W; Kansal A; Vicente C; Deniz B; Sarda S J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475 [TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Hettle R; Harty G; Wong SL J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273 [TBL] [Abstract][Full Text] [Related]
11. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition. Janković SM; Kostić M; Radosavljević M; Tesić D; Stefanović-Stoimenov N; Stevanović I; Raković S; Aleksić J; Folić M; Aleksić A; Mihajlović I; Biorac N; Borlja J; Vucković R Vojnosanit Pregl; 2009 Jul; 66(7):556-62. PubMed ID: 19678581 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249 [TBL] [Abstract][Full Text] [Related]
14. An economic evaluation attached to a single-centre, parallel group, unmasked, randomized controlled trial of a 3-day intensive social cognitive treatment (can do treatment) in patients with relapsing remitting multiple sclerosis and low disability. van Mastrigt GA; Evers SM; Heerings M; Visser LH; Ruimschotel RP; Hussaarts A; Duyverman L; Valkenburg-Vissers J; Cornelissen J; Bos M; van Droffelaar M; Jongen PJ J Med Econ; 2019 Oct; 22(10):967-980. PubMed ID: 31084442 [No Abstract] [Full Text] [Related]
15. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L; Guo S; Kinter E; Fay M J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961 [TBL] [Abstract][Full Text] [Related]
18. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659 [TBL] [Abstract][Full Text] [Related]
20. Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis. van Eijndhoven E; Brauer M; Kee R; MacEwan J; Mucha L; Wong SL; Durand A; Shafrin J J Med Econ; 2020 May; 23(5):474-483. PubMed ID: 31903813 [No Abstract] [Full Text] [Related] [Next] [New Search]